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ABSTRACT
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Chemical Species, Biomolecules and Biotargets (Analytes)
using receptor functionalized metal nanoparticles and
Dynamic Light Scattering.
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DETECTION OF ANALTYES USING METAL
NANOPARTICLE PROBES AND DYNAMIC
LIGHT SCATTERING

the assay solutions. (3) When it can be rotated, samples may
be continuously added and removed from the carousel using
removable assay solution containers as shown in (c). This
mode can be set for continuous measurement of multiple
samples at a preset time interval. (4) The relative angle
between incident light beam and scattered light beam that will
be detected by the detector is typically an angle between 0-90
degree. Illustrated here the angle is approximately 13-25
degree. (5) The carousel may be replaced by a microfluidic
device which can be placed and removed from the carousel.
(6) The number of sample holders and detectors can be 1 or
any other number.
FIG. 4 is the average scattered light intensity of a gold
nanorod (GNR, dimension of 10 by 40 nm), 40 nm (GNP40),
and 98 nm (GNP98) spherical goldnanoparticles measured at
different concentrations by DLS.
FIG. 5 is: (a) The chemical structures and (b) TEM images
of GNP and GNRparticles. (c) The UV-Vis absorption spectra of GNP, GNR probes and their conjugates with an antibody pair: GNP-dAb and GNR-cAb. The two antibodies are
anti-free PSA antibodies. (d) The size distribution measured
from DLS ofunconjugated GNP, GNR, and (e) their conjugates with antibody pairs.
FIG. 6 shows DLS data in particle size distribution of an
assay solution with 1.0 ng/mL of f-PSA in sample solution
(a). The assay results off-PSA standard solutions (b) obtained
from DLS analysis. The assay results are expressed as the
numerical ratio of area A versus area B as shown in (a).
FIG. 7. (a) The chemical structures of PAA-GNP (top) and
PEG-GNP (bottom). The UV-Vis absorption spectra of citrate-GNP (b ), PAA-GNP (c) and PEG-GNP (d) at PBS buffer
solutions (pH 7.4) with different concentrations of NaCl (legends are NaCl concentrations)
FIG. 8. shows: (a) DLS data (particle size distribution) of
the assay solution with 0 and0.1 ng/mL f-PSAin solution. (b)
The plots of hydrodynamic diameters of nanoparticles versus
f-PSA concentration. Two sets of assays were conducted. The
assay showed both good intra-assay and inter-assay reproducibility. Results were obtained from the Cool Batch40 DLS
system from Precision Detectors, Inc.
FIG. 9 shows assay results for total PSA in standard solutions using 100 nm GNP antibody conjugate probes. The 100
nm GNP probes were prepared by non-covalently adsorbing
a matched monoclonal anti-total PSA antibody pairs to two
batches of gold nanoparticles. The assay results were
expressed as average particle size diameter of the assay solution. The assays were done in two different concentration
ranges: (a) 0.2-10 ng/mL and (b) 0.001to1 ng/mL.
FIG. 10 shows assay results in duplicate for total PSA
secreted by PC3 cells in the supernatants using 100 nm GNP
antibody conjugate probes. The results were expressed in
average particle size. The 100 nm GNP probes were prepared
by non-covalently adsorbing a matched monoclonal anti-total
PSA antibody pairs to two batches of gold nanoparticles. The
cell supematants were collected after 24 hours of growth.
Samples PC3Al, PC3Bl, and PC3Cl had approximately 1
million, SOOK and 250K cells in the culture dish. To conduct
the assay, 2 µL of cell supernatant was added to 40 µL of
mixed nanoprobe solution. After incubating the solution at
room temperature for 5-10 min, results were read by DLS.
FIG. 11 is the assay results of four human serum samples
using the same probes as described in FIG. 7 and FIG. 8.
FIG. 12 is the assay results of four sample solutions that
contain actin at a concentration of 34.5, 17 .3, 8.6, and 4.3
ng/mL of actin, respectively. The actin solutions were cell
lysates. The two probes were prepared by conjugating a
matched monoclonal anti-actin antibody to two batches of

CROSS REFERENCE TO RELATED
APPLICATIONS
The present application claims priority to U.S. Provisional
Application 61/018,719 filed Jan. 3, 2008 and U.S. Provisional Application 61/034,334 filed Mar. 6, 2008. Priority
under 35 USC 119 is claimed to said provisional applications
and the applications are incorporated by reference.
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5

10

15

The U.S. Govermnent may have certain rights to the invention based on National Science Foundation CAREER Award
DMR 0552295 and DMI Award 0506531.
20

FIELD OF THE INVENTION
The present invention relates to systems and methods for
detecting Chemical Species, Biomolecules and Biotargets
(all termed as Analytes) using receptor functionalized metal
nanoparticles. Receptor is a general term for any chemical
species and biomolecules that can interact with the analytes
through covalent or non-covalent chemical interactions.
BACKGROUND
There is a need to detect various Chemical Species, Biomolecules and Biotargets for a variety of purposes, such as
medical diagnosis, human and animal health monitoring, life
science research, drug screening and pharmaceutical development, environmental protection, industrial process monitoring, food safety monitoring, detection of illegal drug
usage, homeland security, monitoring of other chemical and
biological process.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic illustration of the invention including
three different embodiments. The illustration is an example
based on a homogeneous immunoassay using gold nanoparticles (GNP) coupled with dynamic light scattering (DLS)
measurement. In embodiment A, two different probes are
used. The probes are gold nanoparticles conjugated with a
matched antibody pair. In embodiment B, a single type of
probe is used. The analyte contains multiple binding sites
with the probe, therefore, can cause nanoparticle aggregation
upon binding with the receptors on the probes. In embodiment C, a single type of probe is used. However, the binding
between analytes and probes does not cause particle aggregation. Instead, an aggregation inducer is present to introduce
nanoparticle aggregation. The analyte and aggregation
inducer compete with each other to bind with the probes.
FIG. 2 is a basic design of a DLS system.
FIG. 3 a-c represents schematic diagrams of DLS system
implementing a multiple sample platform for simultaneous
DLS measurement of multiple samples using a plurality of
detectors (a, b) or continuous DLS measurement of multiple
samples using a single detector and a rotatable carousel (c).
FIG. 3(b) is a partial side view of the system shown in FIG (a).
Note: (1) The sample platform can be movable or fixed. The
platform shown comprises 12 fixed assay solution containers
(in this case, 12 microwells ), or removable containers to hold

45

50

55

60

65

US 8,883,094 B2
3

4

100 run GNPs. The first two columns (blue and dark red) are
DLS data in average particle size from two different assays
and the third column (light yellow) is the average of the two
assay results.
FIG. 13 shows the hydrodynamic diameter (Dh) change of
assay solutions of mouse IgG mixed with two different gold
nanoparticle probes after incubating at 37° C. for 2 hours.
(-0-: a control made of mouse IgG with 0.1 nM BSA conjugated GNPs; -fl-: mouse IgG mixed with a 0.1 nM goat-anti
mouse conjugated GNPs. The assay using BSA conjugated
GNP as a control for the study)
FIG. 14 is the results of a direct assay for mouse IgG
detection using 0.01 nM goat anti-mouse IgG conjugated
GNPs (GNP-anti-IgG). Measured data was fitted into a logistic model using a four parameter Logistic fitting without
weighting. (LLOD=0.0078 ng/mL, 3a, R=2; y=187.55435+
R 2 =0.9994;
(35.46758-187.55435)/(1+x/46.97037) 06302 ,
error bar: standard deviation.
FIG. 15 is the results of a competitive assay for mouse IgG
detection using two nanoparticle probes, GNP-IgG and GNPanti-IgG. Here GNP-anti-IgG serves as the probe, and GNPIgG serves as an aggregation inducer. Analyte mouse IgG
competes with GNP-IgG to bind with GNP-anti-IgG. The
concentration of both GNP-anti-IgG and GNP-IgG probes
was 0.1 nM. Each assay solution was incubated at room
temperature for 4.5 hours. Measured data was fitted into a
logistic model using a four parameter Logistic fitting without
weighting. (LLOD=283.0036ng/mL, 3a, R=2; y=42.21247+
(71.12096-42.21247)/(1 +x/5023.40461) 076428 , R 2 =0.9895,
error bar: standard deviation
FIG. 16 is a schematic illustration ofa homogeneous detection of DNA using gold nanoparticle probes and dynamic
light scattering. FIG. 16 discloses SEQ ID NOS 1-3, respectively, in order of appearance.
FIG. 17 is the UV-Vis absorption spectra (a) and size distribution (b) of gold nanoparticles (AuNPs) before and after
DNA conjugation.
FIG.18 is the size and size distribution (in diameter, run) of
DNA-AuNP assay solutions in the presence of perfectly
matched target DNAs (a), and single base pair-mismatched
DNAs at a concentration of 10 µM (b ).
FIG. 19 is the average diameters of the assay solution
containing different concentrations of target DNAs as determined from DLS measurements and plotted against the target
DNA concentrations.

mers or other chemical species). A sample solution suspected
of including at least one analyte is contacted with the probes
to form an assay solution, wherein in a presence of the analyte
a portion of the probes in the analyte comprising solution
become aggregated. Dynamic light scattering (DLS) is used
to quantify the analyte by measuring the degree of aggregation of the assay solution. At least a presence of, and generally
also the concentration of, the analyte in the sample solution is
determined from DLS data obtained from the assay solution
as determined by DLS. The concentration of the analyte
determined can be used to base a medical diagnosis or prompt
further tests to base a diagnosis, such as whether an individual
has (or is likely to have) cancer, or other purposes such as
envirorunental monitoring.
In another embodiment (the embodiment B as illustrated in
FIG. 1), referred to herein as a single pro be type embodiment,
a first probe is the only probe type provided. This probe
contains multiple copies of a single type or mixed types of
receptors on one nanoparticle. In this embodiment the analyte
can have multiple binding sites and the same probe type can
bind to the multiple sites of the analyte to create nanoprobe
aggregates. By way of example only, the nanoparticles may
be conjugated with a layer of multiple polyclonal antibody
which can bind with different epitopes of an antigen. Such
binding will cause probe aggregation which is detectable by
DLS. Another example is a nanoparticle probe with a layer of
metal ion-binding ligands attached to the surface. The probe
can form a coordination complex with the metal ion through
ligands attached to the probe. When the probe is contacted
with a sample that contains the metal ion as analyte, nanoparticle probe aggregation will occur due to complex formation,
which can be detected by DLS.
In another embodiment (the embodiment A as illustrated in
FIG. 1), referred to herein as the multiple probe type embodiment, the method includes both a plurality of first probes and
a plurality of second probes, wherein the second probes comprise a metal nanoparticle conjugated with a second receptor
that is different from the first receptor. The first and second
metal nanoparticles can be the same or different. In this
embodiment the first and second receptor can both be selected
to bind with the analyte and generally recognize separate sites
on the analyte to bind. In this way, the respective receptors do
not generally inhibit the other receptor's binding.
In the case of receptors comprising antibodies regarding an
antigen target, the antibody combination should be qualified
as "matched pairs", meaning that they can recognize separate
epitopes on the antigen so they do not significantly hinder
each other's binding. In this particular case, the first and
second receptors may be referred to herein as in ELISA as the
"capture antibody" and the "detection antibody". However,
the present invention has little relation to ELISA. ELISA is a
heterogeneous multiple step immunoassay. Embodiments of
the present invention provide a homogenous assay that
removes the ELISA need for binding the capture antibody to
a solid phase typically attached to the bottom of a plate well,
adding antigen and allowing complexation with the bound
antibody, washing to obtain unbound product, and a second
binding step where the detection antibody is allowed to bind
to the antigen. Another difference is the use of Dynamic light
scattering (DLS) to quantify the analyte, as compared to
ELISA which achieves quantitation by measuring the amount
of labeled second antibody bound to the matrix through the
use of an enzymatic probes, fluorescent probes, or radioactive
probes.
In a third embodiment (the embodiment C as illustrated in
FIG. 1), the method involves the use of plurality of a single
probe with multiple copies of receptors conjugated to the
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DETAILED DESCRIPTION
Embodiments of the invention pertain to a highly sensitive,
fast and convenient homogeneous one-step analytical assay
for monitoring and detecting Chemical Species, Biomolecules and Biotargets (all termed as analytes) including but
not limited to, proteins, antibodies, antigens, enzymes,
nucleic acids, hormones, drugs, drug intermediates, environmental polluting chemicals and species, chemical and biological warfare agents, bacteria and viruses, synthetic chemical substances.
In a general embodiment, the invention pertains to an analytical method for the detection of analytes comprises the
steps of providing a plurality of probes each comprising a
metal nanoparticle conjugated with multiple copies of the
same or different receptors. FIG. 1 is a general illustration of
the invention. The illustration is an example based on a homogeneous immunoassay using gold nanoparticles (GNP)
coupled with dynamic light scattering (DLS) measurement.
The receptor can be a natural receptor (e.g. antibody, protein,
DNA, etc.) or a synthetic receptor (e.g. molecules, ions, poly-
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nanoparticle surface. The probe will mainly bind to one site of
the analyte. The probe particles can form aggregates by a
molecule or material different from the analyte. This molecule or material can be called as "aggregation inducer". This
molecule or material can be another chemical species, a different nanoparticle, or a material that is co-existed with analyte in the sample solution, or that is added to the sample
solution from sources other than the sample solution. The
aggregation inducer competes with analyte to bind with the
probe. The binding between probes and analyte will inhibit
the probe aggregation caused by aggregation inducer. When
the probes are contacted with the sample solution, the probes
will form aggregate introduced by the aggregation inducer
molecule. The analyte will not cause or cause much less
aggregation of nanoparticle probes than the aggregation
inducers. Therefore, ifthere is analyte in the sample solution,
there will be less degree of probe aggregation. The degree of
probe aggregation is inversely proportional to the analyte
concentration. An example for this embodiment is a competitive immunoassay that utilizes a probe containing a single
type of primary antibody on the nanoparticle surface. This
probe may be aggregated together by mixing with a secondary antibody solution. In this case, the secondary anti body is
the aggregation inducer. For example, ifthe probe contains a
primary antibody raised from mouse, a goat anti-mouse IgG
may be used as an aggregation inducer. When the probe
solution is mixed with sample solution that contains the antigen, the antigen molecule will compete with the secondary
antibody to bind with the probe. Because the antigen-probe
binding will not cause probe aggregation. As a result, when
antigen is present in the sample, less degree of probe aggregation will occur compared to when antigen is absent from the
sample. The antigen concentration in the sample solution can
be quantified by DLS measurement and is inversely proportional to the degree of nanoparticle aggregation.
Quantitation according to embodiments of the present
invention comprises directing light (e.g. ultraviolet, visible,
near infrared or infrared) toward the analyte comprising solution mixed with plurality of nanoparticle probes, and measuring a scattered light signal from the assay solution. At least a
presence of, and generally also the concentration of, the analyte in the sample solution is determined from using dynamic
light scattering to obtain DLS data from the assay solution.
DLS data includes but is not limited to particle size, and/or
particle size distribution and/or diffusion coefficient of particles in the assay solution. The concentration of the analyte
determined can be used for multiple purposes as described
herein, e.g., to base a medical diagnosis or prompt further
tests to base a diagnosis, such as whether an individual has (or
is likely to have) cancer.
The nanoparticles are generally metals, such as gold or
silver which are both known to provide large scattering cross
sections (Yguerabide, J.; Yguerabide, E. E. Anal. Biochem.
1998, 262, 137). The nanoparticles can have different shapes
and chemical compositions such as spherical nanoparticles,
nanorods, nanoshells, alloyed nanoparticles (nanoparticles
with more than one metal components), nanocages, nanorice,
etc. Other nanoparticles or colloidal particles that provide
large scattering cross sections may be useful as well. The
present invention is generally described herein with respect to
gold nanoparticles. For example, gold nanoparticles, including spherical particles, nanorods or nanoshells with a size
ranging from 10 s to 100 s nanometers, provide exceptionally
large light scattering cross sections in the surface plasmon
resonance wavelength region. The magnitude oflight scattering by a gold nanoparticle is orders of magnitude higher than
light emission from strongly fluorescing dyes such as fluo-

rescein. This strong light scattering property of gold nanoparticles has been applied to optical microscopic imaging of
biological cells for qualitative evaluation, but not for quantitative analysis and assays in homogeneous solutions by
dynamic light scattering method. The strong light scattering
makes gold and silver nanoparticles as excellent optical
probe/tracer for analytical applications.
Receptors can be any moiety known to associate to a given
target analyte. In competitive assay embodiment, receptor
will also bind to the aggregation inducers. Analytes and
aggregation inducers compete to bind with the receptor.
The receptors are adapted for binding to an analyte. Receptors can include, but are not limited to, antibody, DNAs,
RNAs, proteins including enzymes, cells or cell components,
biomimetics, synthetic molecules or materials which can specifically bind to the analyte. Biomimetic receptors can
include molecular imprint antibodies, DNA-based aptamers,
and peptide nucleic acids (PNA).
The receptor molecules (natural and synthetic) will be
attached to the metal nanoparticles through covalent or noncovalent chemical interactions to prepare the probe. Methods
for attachment ofbioreceptor molecules such as antibody to
gold nanoparticles through non-covalent chemical interactions have been well known and commonly practiced. For
covalent attachment, the nanoparticles should have at least
one chemical functional group such as carboxylic acid or
amine on the particle surface, or any other suitable functional
groups that can link the receptors to the nanoparticles. The
receptor molecules will react with the chemical functional
group to form a covalent chemical bonding.
Analytes can be any chemical species, biomolecules and
biotargets. Chemical species are any natural and synthetic
chemical substances (neutral or charged, with or without a
confirmed molecular structure), ions such as mercury (II),
lead (II), polymers, materials, drugs and pharmaceuticals,
drug candidates, or any other chemical substances. Biomolecules are generally biochemical substances, such as proteins, enzymes, antibodies, antigens, haptens, drugs, drug
intermediates or fragments, hormones, polysaccharides,
metabolites, nucleic acids. Biotargets are biological species
or living systems, such as bacteria, virus or related components. The sample that is to be assayed using the invention
described can be biological or non-biological based. The
biological sample can be, but is not limited to, human and
other animal blood, plasma, serum, urine, saliva, sputum, or
other bodily fluids; cell supernatants, cell media, or cell
lysate; tissue extracts. The non-biological samples can be, but
are not limited to, water from different resources, liquid
extracts from different materials and objects, etc. The sample
solution may or may not need to be pre-processed chemically
or physically before conducting the assay. The processing is
to eliminate large particles or other factors that may interfere
significantly with the assay results. Examples of physical
processing include filtration, centrifuge, ultrasonication, precipitation, heating or cooling etc. Examples of chemical processing include adding a chemical or chemicals such as
sample diluents, surfactants, oxidation or reduction reagents,
disinfectants, cell lysing reagents, denaturing and de-hybridization agents to pre-treat the samples. The amount of the
sample used for the assay can vary from nano liters to microliters. A portion of the sample solution may be divided into
multiple smaller portions of samples using a liquid handling
system or micro or nanofluidic device for multiple analysis.
DLS is a technique used widely for particle size and size
distribution studies (Berne, B. J.; Pecora, R. Dynamic light
scattering: with applications to chemistry, biology, and physics; 1976, by Wiley: New York.) The principal of DLS has
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been established more than three decades ago and a wide
range of DLS instruments and systems are commercially
available. This technique is based on the Brownian motion of
spherical particles which causes a Doppler shift of incident
laser light. The diffusion coefficient of particles are measured
and the size of the particles is calculated according to the
Stokes-Einstein relation. Although studies have been
reported on bioconjugation of metal (e.g. gold) nanoparticles
and biomolecular interaction-directed nanoparticle aggregation, prior to the present invention, DLS has not been disclosed in conjunction with metal (e.g. gold) nanoparticle
probes for homogeneous and quantitative assays. Applied to
the embodiments of the present invention, DLS can detect
particle size change, or size distribution change caused by the
formation of nanoparticle dimers, trimers, oligomers, and
aggregates. This capability makes DLS a suitable analytical
tool for a quantitative assay according to embodiments of the
invention.
Metal nanoparticles used in the invention can be monodispersed or poly-dispersed in terms of size. "Poly-dispersed"
means the nanoparticle solution contains nanoparticle with
different size ranges, while "monodispersed" means all nanoparticles have the same or similar sizes. The metal nanoparticles used in the invention generally have an average size in
diameter in the range of 1-1000 nm. The nanoparticles generally have a layer of molecules, ions, or polymers attached
covalently or non-covalently on the particle surface to prevent
nanoparticle from de-stabilization. These molecules, ions and
polymer may or may not have thiol groups or amine groups in
them. Thiol and amine groups have high affinity towards gold
nanoparticles. Other molecules with high affinity for gold and
silver nanoparticles may be used. Citrate is a common ligand
used to protect and stabilize gold and silver nanoparticles.
The citrate molecules bind with gold and silver nanoparticles
through electrostatic interactions. The preparation of gold
nanoparticles or colloids stabilized by citrate molecules was
established more than 5 decades ago and has been used since
then (Turkevitch, J.; Stevenson, P. C.; Hiller, J. Discuss. Faraday Soc. 1951, 11, 55; and Frenz, G. Nature Phys. Sci. 1973,
241, 20.) Polymers or smaller oligomers such as oligo(ethylene oxide) (OEG) or poly(ethylene oxide) (PEG) with one or
multiple thiol groups on the polymers are also used to modify
gold and silver nanoparticle surface. OEG or PEG-protected
gold nanoparticles are much more stable than citrate-stabilized nanoparticles in high salt content solutions such as
human blood and other biological fluids. The typical salt
concentration of these biological fluids is about 100-200 mM.
A new metal particle is also described herein. This metal
particle has a layerof poly( acrylic acid) (PAA) attached to the
particle surface. The PAA are attached to nanoparticles
through non-covalent interactions such as electrostatic, van
der Waals interactions and hydrogen bonding. Similar to
OEG and PEG-protected nanoparticles, PAA-protected
nanoparticles are also much more stable in high salt content
solutions.
New methods are also described regarding how to extract
an analyte (e.g. antigen) concentration from DLS analysis.
The method described obtaining quantitative data from DLS
measurements.
The present invention is not limited to the disclosure above
or examples provided below. The invention can be used for
other applications, for example, embodiments of the invention can generally be used for the detection of any chemical,
biological molecule or substance that can cause nanoparticle
aggregation or deaggregation after metal (e.g. gold) nanoparticles are modified with appropriate receptors towards these
species. As noted above, other than gold nanoparticles,

embodiments of the invention may also use silver nanoparticles or other types of nanoparticles that provide large scattering cross section and are detectable at very low concentration using DLS technique. Moreover, the invention is not
limited to the detection of chemicals and biological molecules in biological samples. It may also be used for detection
of chemical substances in non-biological samples.
EXAMPLES
10

15

The Examples provided below are all non-limiting
examples. Specific materials disclosed are only exemplary
materials. For example, the metal nanoparticles are not
restricted to gold nanoparticles (GNP), the analytes are not
limited to biomolecules.
Example 1
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A One-Step Homogeneous Immunoassay for Cancer
Biomarker Protein Detection
Millions of people around the world face the risk of cancer,
which have been one of the leading causes of mortality. An
early detection of cancer can significantly improve the treatment and survival rate of cancer patients. As tumor develops,
the cells, tissues and organs can release, increase or decrease
the release of certain chemicals in the circulating blood system. These specific chemicals are called biomarkers. Biomarkers detection and monitoring has tremendous significance
for cancer diagnosis and treatment.
An ideal immunoassay technique for biomarker detection
is expected to meet the following 4-S criteria: simple, highly
sensitive, highly specific, and requires small volume of
samples. Despite the existence of numerous assay and sensor
technologies, an ideal bioanalytical tool that meets all these
criteria has yet to be developed. Most bioassay techniques or
biosensors either lack the high sensitivity, involve large volume of samples, and/or complicated assay procedures/data
analysis that can only be done by trained professionals. A
typical heterogeneous sandwich-type immunoassay such as
ELISA, chemiluminescence immunoassay, involves the antibody immobilization, multiple steps of incubation and washing cycles, followed by signal amplification and reading.
From the initial antibody immobilization to the final reading
of the assay results, the entire immunoassay can usually take
hours to days to complete. A traditional immunoassay is
rather time-consuming and labor-intensive. Although in
medical testing labs, these assays are all done by fully automated instruments, such instruments are bulky, expensive to
manufacture and to maintain due to complicated assay procedures. Such systems are not suitable for point-of-care purposes and for individual research labs. Also, a typical plate
immunoassay requires relatively large volume of samples ( 50
to 100 s µL), therefore, is not suitable for a single drop of
blood analysis. Protein microarrays have been developed to
minimize the amount of samples needed for the assay, with
another distinctive advantage of multiplexing capability.
However, protein microarrays involve the use of sophisticated
software for data analysis, and the cost for assay development
and validation is prohibitively too high for routine purpose
and for most research labs to adopt for biomarker research.
As illustratedinFIG.1, embodimentA, goldnanoparticles
(GNP) in the size range of about 1-1000 nm with a large light
scattering cross section, are used as an optical probe to couple
with an antibody pair (capture and detector antibody, cAb and
dAb) for a specific cancer biomarker. These two nanoparticle
probes (GNP-cAb and GNP-dAb) are then mixed with a
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sample solution, which may or may not need to be pre-filtered
or chemically treated to remove large particles. In the presence of antigen, the antigen-antibody binding will lead to
nanoparticle aggregation. The formation of nanoparticle
aggregates versus individual nanoparticle probes can be
quantified by DLS, and this quantitative information can be
correlated to the antigen concentration. Alternatively, if the
distribution peaks of individual particles and particle aggregates are not separated, then the average particle size (for
example, it can be expressed as hydrodynamic diameter)
increase due to aggregate formation will be used to correlate
with the antigen concentration.
Gold nanoparticles, including spherical particles, nanorods and nanoshells with a size ranging from 10 s to 100 s
nanometers, are known to have a large light absorption and
scattering cross section in the surface plasmon resonance
(SPR) wavelength region. In normalized terms, the scattering
cross section of a 30 nm gold particle at its SPR region is
about 250 times larger than a 30 nm polystyrene particle. As
compared to fluorophores, the scattering light intensity from
a 60 nm gold nanoparticle is four to five orders of magnitude
higher than a strongly fluorescent fluorescein molecule
(Yguerabide, J .; Y guerabide, E. E. Anal. Biochem. 1998, 262,
137).
Dynamic light scattering (DLS), also known as photon
correlation spectroscopy or quasi elastic light scattering, is a
technique used widely for particle size and size distribution
analysis. This technique is based on the Brownian motion of
spherical particles which causes a Doppler shift of incident
laser light. The diffusion coefficients of particles are measured and the size of the particles is calculated according to
the Stokes-Einstein relation. Although a very limited number
of studies have been reported more than three decades ago to
use DLS for quantitative and homogeneous immunoassay, in
these previous works, polymer latex particles were used as
light scattering enhancer to conjugate with antibody as the
optical probe (Cohen, R. J.; Benedek, G. B. Immunochemistry 1975, 12, 963-966. Von Schulthess, G. K.; Cohen, R. J.;
Benedek, G. B. Immunochemistry 1976, 13, 963-966). Compared to gold nanoparticles at similar sizes, the scattering of
polymer latex particles is much weaker. This low scattering
intensity is not sufficient to suppress the scattering signal
from other particles in the sample solution, making this light
scattering immunoassay technique unsuitable or significantly
limited for detection of low abundance protein analytes. By
using gold nanoparticles as the probe, the scattered light
intensity from gold nanoparticle probes is sufficiently strong
enough to suppress the background light scattering arising
from the sample solution, therefore, providing much
enhanced sensitivity to the immunoassay.
The inventors first developed a homogeneous one-step
immunoassay for prostate cancer biomarker detection using
the embodiment A as illustrated in FIG. 1 (Huo, Q. et al. J.
Am. Chem. Soc. 2008, 130, 2780-2782). In this work, a
spherical gold nanoparticle with a diameter of 40 nm and a
gold nanorod with a dimension of 10 by 40 nm were used to
prepare the matched antibody conjugate probes. In a feasibility study, the inventors analyzed the detection limit of gold
nanoparticles and nanorods using DLS. FIG. 4 shows the
average scattered light intensity of a gold nanorod (GNR,
dimension of 10 by 40 nm), 37 nm (GNP37), and 98 nm
(GNP98) spherical gold nanoparticles measured at different
concentrations by DLS. From this data, the detection limit of
three gold nanoparticle materials: GNR, GNP37, and
GNP98, was determined to be 0.4 µM, 0.02 µMand 0.7 fM,
respectively. This high sensitivity makes gold nanoparticles

as very attractive light scattering probes for immunoassays
according to embodiments of the invention.
Based on the principal as outlined in FIG. 1, the inventors
developed an immunoassay using the invention to detect free
prostate specific antigen (free PSA), a biomarker protein
associated with prostate cancer. Prostate specific antigen
(PSA) is an FDA-approved biomarker for prostate cancer
diagnosis. The total PSA concentration of a healthy male is in
the range of a few ng/mL and the free PSA (f-PSA) concentration is typically less than 1 ng/mL, in the range of 10-25%
of the total PSA. Free PSA is the unbound form of prostate
specific antigen. Studies have shown that the percentage of
f-PSA in total PSA is lower in patients with prostate cancer
than those with benign prostate hyperplasia. The free PSA
level is now being introduced and studied as an additional
biomarker for prostate cancer screening and diagnosis.
In this study, the inventors prepared two types of gold
nanoparticles: one is a citrate-stabilized spherical gold nanoparticle (Ct-GNP, diameter 37 nm), and another one is a
cetyltrimethyl ammonium bromide (CTAB)-protected gold
nanorod (CTAB-GNR, 10 by 40 nm) (FIG. Sa). The two
antibodies were conjugated to the two nanoparticles by noncovalent adsorption. This process is known and familiar to
those who are skilled in this field. A TEM image and UV-Vis
absorption spectra of GNP and GNR are shown in FIG. Sb and
c. The particle size and size distribution was analyzed by DLS
(FIG. Sd). The successful conjugation of nanoparticles with
detector antibody and nanorods with capture antibody was
first confirmed by UV-Vis spectral analysis and DLS measurement (FIG. Sc and e). Compared to the original GNPs and
GNRs, the SPR absorption band of the nanoparticles were
shifted slightly due to the surface chemistry change of the
conjugated particles. The size of the conjugatednanoparticles
also increased from 3 7 to 57 nm and 30 to 37 nm, respectively,
for the GNPs and GNRs. These data suggest that the two
antibody were successfully conjugated to GNP and GNRs
respectively. It is estimated that the number of antibody
attached to the nanoparticle surface is between 10-100 per
particle. Larger particle size will lead to attachment of more
antibodies to the particle surface.
The homogenous immunoassay of f-PSA was then conducted in solution using the conjugated nanoparticles and
nanorods. The two nanoprobes were mixed in 1:2.5 (GNPdAb:GNR-cAb) ratio and then added to the standard f-PSA
solutions with different concentrations. The GNR probe was
added in excess and used as an internal reference. The assay
solution was incubated at room temperature for 30 min before
DLS analysis. DLS analysis was conducted on a Cool
Batch40 system from Precision Detector, Inc.
FIG. 6a is a typical size distribution of mixed nanoprobe
solution in the presence of 1 ng/mL of f-PSA. For the pure
nanoparticle and nanorod conjugates, only one size distribution of particles was observed from the distribution, as seen
from FIG. Se. With f-PSA added to the nanoprobe solution,
DLS measurement detected two groups of particle sizes (FIG.
6a, peak area A and B), one is centered at below 60 nm
representing individual nanoparticles and nanorods (area B),
and one above 100 nm corresponding to nanoparticle-nanorod oligomers (area A). The relative ratio (here we used the
scattered light intensity ratio) of nanoparticle oligomers in the
size range of 60-500 nm (area A) versus individual nanoparticles in the size range of 20-60 nm range (area B) can be
numerically calculated from the size distribution curve. FIG.
6b is the plot of this numerical ratio versus f-PSA concentration. With increased concentration off-PSA, the relative percentage of nanoparticle oligomers increased while the percentage of individual nanoprobes decreased. Using the same
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nanoprobes in buffer solution, we conducted the analysis of
an unknown sample solution (f-PSA concentration at 0.5
ng/mL ). The determined concentration corresponds very well
to the true concentration of the sample (FIG. 6b, data indicated with a red asterisk).
The immunoassay demonstrated by the inventors offers
several incomparable advantages over traditional immunoassay and other state-of-the-art bioanalytical techniques: (1) an
extremely simple assay process; (2) requires minute amount
of samples (0.1 to several µL) for the assay, which means we
can detect multiple biomarkers from a single drop of blood
sample taken from a fingertip; (3) high sensitivity (fM to aM
in concentration, or fg in absolute mass) without any amplification steps; (4) low cost with high throughput analysis
capability; (5) extremely fast analysis time (a complete assay
can be done in less than 5 minutes).

nificant aggregation, while citrate-stabilized gold nanoparticles aggregate severely at a salt concentration of 30 mM.
The PEG-protected GNPs can exist in a buffer solution with
a NaCl concentration of 100 mM without significant aggregation. The significantly increased stability of PAA and PEGprotected gold nanoparticles was further confirmed by size
analysis using DLS (data not shown here). The physiological
salt concentration of human blood is in the range of 100-150
mM. Both PAA and PEG-protected gold nanoparticles synthesized in our study can be suitable as a nanoprobe for future
assay of biological samples.
Both PAA and PEG-protected GNPs were used to conjugate with anti-f-PSA antibody pairs and an immunoassay of
f-PSA conducted. Very similar immunoassay results were
obtained from both nanoparticle conjugates, but only data
from PEG-GNPs are presented here as an illustration. The
conjugation of antibody pairs for PAA-GNPs was done
through a simple non-covalent adsorption, similar to conjugating antibody to citrate-protected GNPs. The conjugation
of antibody pairs to PEG-GNPs was done by covalent chemistry through amide bond linkage. After conjugation, the average diameter of the nanoparticles increased in average by
10-15 nm, corresponding to the expected size increase from
PEG-GNPs or PAA-GNPs covered with a layer of antibody.
Immunoassay of f-PSA in standard solution was then conducted using these nanoparticle probes. For this assay, PEGGNPs conjugated with capture and detector anti-f-PSA antibody were mixed in equal amount and the average
nanoparticle size increase caused by nanoparticle aggregation was monitored and analyzed by DLS. FIG. Sa is the size
distribution of nanoparticles in the assay solution with 0
ng/mL and 0.1 ng/mL f-PSA present, and FIG. Sb pertain to
the assay results from two different experiments. From FIG.
Sa, one can see that when analyte f-PSA is present, the average particle size of the assay solution is increased compare to
assay solution that has no analyte f-PSA in the sample solution (compare the two dark grey-colored distribution peaks,
the white-colored particle distribution peaks are from impurities). The average particle size (here expressed as the hydrodynamic diameter) increases proportionally with increased
analyte concentration, as seen from FIG. Sb. The assay of
each sample solution was conducted in duplicates. The standard deviation of each concentration tested is very small,
indicating excellent intra-assay reproducibility, while the
inter-assay reproducibility is also very good.
The following seven biomarkers are currently being tested
as target analytes for the immunoassay development: freePSA, total PSA, CA 125, CA 15.3, CA 19-9, Her-2/neu and
CEA. These biomarkers are associated with one or more of
the following cancers: prostate, breast, ovarian, pancreatic,
liver, lung and colorectal cancer. Other than CEA, all other
biomarkers are FDA-approved serum biomarkers. The
method described herein can be essentially applied to any
biomarker. Thus, the bioassay technique described herein is
not limited to these particular cancer biomarkers. It may also
be extended to the analysis of other proteins, antibodies,
antigens, DNAs, RNAs, as well as other biological targets.
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Example 2
Improved Homogeneous Immunoassay Using New
Robust Gold Nanoparticle Probes
Development of robust gold nanoparticle probes: Two new
nanoparticle probes with improved stability in high ionic
strength buffer solutions than citrate-stabilized gold nanoparticles were developed. One is a spherical gold nanoparticle
stabilized by poly( acrylic acid) (PAA) and another one is a
thiolated poly( ethylene glycol) ligand (PEG)-stabilized gold
nanoparticle (FIG. 7a). Both nanoparticles were obtained
from the surface modification of citrate-stabilized gold nanoparticles. The PEG-protected GNPs were synthesized
according to the following procedure: Citrate-protected
GNPs with an average core diameter of30-35 nm were first
synthesized according to a reported method (Turkevitch, J.;
Stevenson, P. C.; Hiller, J. Discuss. Faraday Soc. 1951, 11,
55; and Frenz, G.NaturePhys. Sci. 1973, 241, 20). Then 1 mL
aqueous solution of a thiolated and bifunctional PEG ligand
as shown in FIG. 7, HS-PEG-COOH (MW of PEG: 3000,
from Rapp Polymers) (2xl0- 4 M) was added drop wise into
10 mL of citrate-protected GNPs solution. The mixture was
allowed to shake at room temperature overnight. The HSPEG-COOH ligand functionalized GNPs were purified by
centrifuge and washed with deionized water three times. The
PEG-GNPs were suspended in pure de-ionized water for
further use.
The PAA-protected GNPs were synthesized according to
the following procedure: 1.5 mL of sodium citrate solution
(38.8 mM) was added quickly into a boiling aqueous solution
ofHAuC14 (0.35 mM, 100 mL) under vigorous stirring. After
boiling for 15 min, 2 mL of PAA aqueous solution (27
mg/mL, pH: -3) was added drop wise to the above solution.
The mixture was allowed to continue boiling for 4 hours.
After the solution was cooled to room temperature, the nanoparticle product was concentrated by centrifuge, washed thoroughly with deionized water twice, followed by washing with
a diluted NaOH solution (pH: 10) twice. The PAA-modified
GNPs were then redispersed in deionized (DI) water for further use
A stability comparison study was undertaken on citratestabilized, PAA and PEG-stabilized gold nanoparticles in
buffer solutions with different salt concentrations using UVVis absorption spectroscopy (FIG. 7b, c and d, respectively).
When gold nanoparticles start to aggregate, the surface plasmon resonance band will shift and become broadened.
According to UV-Vis spectra as shown in FIG. 7, PAA-stabilized GNPs remain stable in a PBS buffer solution with a
NaCl concentration up to 150 mM for 24 hours without sig-
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Development of a one-step homogeneous immunoassay
with improved sensitivity and dynamic range: As shown in
FIG. 4, the light scattering intensity from a 100 nm GNP is
substantially higher than a 40 nm GNP. Most recently, using
GNPs with an average core diameter of 100 nm, we prepared
a set of nanoparticle probes for total prostate specific antigen
(PSA) detection. The average particle size (or so-called
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hydrodynamic diameter of the particles) of the assay solution
was recorded to determine the analyte concentration. The two
matched antibody for total PSA were conjugated to citrateprotected 100 nm GNPs to form two nanoparticle probes.
Using this set of new probes, we were able to detect total PSA
at a concentration as low as 1 pg/mL and extend the dynamic
range of the assay to two concentration ranges: 0.1-10 and
0.001-1 ng/mL (FIG. 9a and b, the two dynamic ranges were
obtained by adjusting different amount of samples added to
the nanoprobe solution: (a) 2 µL sample was added to 40 µL
of probe solution; (b) 20 µL of sample was mixed with 20 µL
of probe solution). While the high concentration range may
be used for routine screening purpose, the low concentration
range may be used for monitoring cancer recurrence after
prostatectomy.
Additionally, we used this assay to detect PSA secreted
from prostate cancer cells, PC3, in cell supernatants collected
after 24 hours of growth. The results are shown in FIG. 10.
Samples PC3Al, PC3Bl, and PC3Cl had approximately 1
million, SOOK and 250K cells in the culture dish. To conduct
the assay, we simply added 2 µL of cell supernatant to 40 µL
of mixed nanoprobe solution. After incubating the solution at
room temperature for 5-10 min, results were read by DLS in
less than 1 min. Comparing PC3Al, PC3Bl, andPC3Cl, the
difference in PSA level can be clearly seen (FIG. 10). The
reproducibility of the assay is very good (data shown in FIG.
10 are duplicates), and assays conducted using different
batches of nanoprobes are also very reproducible. We used a
commercial available total PSA ELISA kit (Anogen) to test
these three cell supernatant samples. The kit was not able to
detect PSA at all from all three samples (the validity of the
assay kit was confirmed by assay of standard PSA solution
included in the kit as well as a number of human serum
samples). These results clearly demonstrated the unmatched
superiority of the new assay described in this invention compared to commercial immunoassay products.
Using the 100 nm GNP probes, the inventors also analyzed
the relative level of total PSA from four different human
serum samples: F6901, M7903, M4406, and M5512. The
particle size analysis results of the assay solutions are shown
in FIG. 11. "F" means the subject is a female and "M" means
the subject is male. These human subjects are known as
normally healthy and have not been diagnosed with prostate
cancer. The first two digits in the sample name is the year
when the subject was born. From the particle size analysis
results, the order of total PSA level should be:
M4406>M7903,,,M5512>>F6901. M5512 has a clinically
determined total PSA level of0.6 ng/mL. This order of total
PSA level reflects roughly the total PSA level difference
between females and males, and males at different ages.
Females should not have or have extremely low level of PSA,
which PSA level increases on males whose age is over 60-65.
Although the absolute value of total PSA level has yet to be
determined through the establishment of an accurate calibration curve, so far these results indicate that the immunoassay
as described in this invention can be used for analyte detection
from human blood and serum samples.

a standard protein solution to monitor the success of the
Western blot. By conjugating a matched pair of monoclonal
antibody with 100 nm GNPs, the inventors developed two
probes for homogeneous assay of actin using dynamic light
scattering. FIG. 12 is the assay results of a series of actin
solutions. The results correspond well to the results obtained
from Western blot. The concentrations of the four samples,
actinl to actin4, are approximately 34.5, 17 .3, 8.6, and 4.3
mg/mL respectively, for the Western blot analysis. The detection limit of actin by Western blot is roughly at 2 mg/mL.
These four samples were diluted 1 million times to 34.5, 17 .3,
8.6, and 4.3 ng/mL respectively, for the homogeneous immunoassay using the invention as described herein. As seen from
FIG. 12, the difference between the four actin samples can be
clearly seen. The sensitivity of the homogeneous immunoassay disclosed in this invention is about six orders of magnitude higher than the traditional Western blot. The amount of
the sample solution used in the present assay (2-5 micro liters)
is also substantially smaller what needs to be used (100 s
microliters) for Western blot analysis.
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Immunoassay for actin using the one-step homogeneous
immunoassay as described in this invention: Actin is a major
component of both the cytoskeletal and contractile structures
in all cell types. It varies in amount, being related to the type
of differentiation and to the functional state of cells and
tissues. Actin can be found in two different forms, the globular or the fibrillar state. Actin is often used in Western blot as
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A one-step competitive and non-competitive assay for
mouse IgG detection using a goat anti-mouse IgG gold nanoparticle probe: In this example, the inventors developed two
formats of assays for mouse IgG (immunoglobulin G) detection using the embodiments B and C as illustrated in FIG. 1.
This study demonstrates the possibility of both competitive
and non-competitive assay using the described invention.
Goat anti-mouse IgG is a secondary antibody that has specific
binding affinity towards mouse IgG, a primary antibody. The
secondary antibody may bind to the Fab, Fab' or Fe region of
the primary antibody, therefore, mouse IgG is considered to
have multiple binding sites for the secondary antibody.
In a first format of assay that we developed for mouse IgG
detection, mouse IgG was directly mixed with goat antimouse IgG conjugated GNPs (40 nm, GNP-anti-IgG). The
conjugation of goat anti-mouse IgG to GNPs was done by
non-covalent adsorption. Due to the multiple binding sites of
primary mouse IgG by the secondary antibody, mouse IgG
caused nanoparticle aggregation. FIG. 13 is an assay conducted with a probeconcentrationof0.1 nM, whileFIG.14 is
an assay conducted with a probe concentration at 0.01 nM. In
this one-step assay, mouse IgG can be detected at concentrations from 7 .8 pg/mL to 50 ng/mL (or approximately 52 fM to
0.33 nM), when the probe concentration was set at 0.01 nM
(results from FIG. 14). The detection limit and dynamic range
of the assay may be adjusted using different concentration of
the nanoparticle probe, as revealed from comparison of FIG.
13 with FIG. 14. This example is an illustration of embodiment B as described in this invention and FIG. 1, using a
single type of probe to detect an analyte that has multiple
binding sites to the single type of receptor attached to the
nanoparticle probe.
A second format of assay developed in this study is a
competitive assay conducted by using both mouse IgG and
goat anti-mouse IgG-conjugated GNPs, that is, GNP-IgG and
GNP-anti-IgG. The GNP-anti-IgG serves as the probe and
GNP-IgG serves as an aggregate inducer to compete with
analyte mouse IgG for binding with GNP-anti-IgG. The
mouse IgG-conjugated GNP probes were prepared by conjugating biotinylated mouse IgG to a streptavidin-coated GNP.
When simply mixing the two GNP probes together in solution
in approximately 1: 1 mole ratio, the two GNP probes will
aggregate together due to specific binding between mouse
IgG and goat anti-mouse IgG molecules. The addition of
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mouse IgG as a target protein in the mixed probe solution
caused a reduction of aggregation between two nanoparticle
probes. The mouse IgG analyte in solution will bind with the
GNP-anti-IgG, therefore, inhibiting the binding of GNP-IgG
with GNP-anti-IgG to form aggregates. The reduction of
aggregation was then used to correlate with the target protein,
mouse IgG, concentration. FIG. 15 shows the assay results
expressed as the average particle size of the assay solution in
hydrodynamic diameter versus the analyte concentration. An
inverse relation is found from the average particle size versus
analyte concentration. In this assay, mouse IgG can be
detected at a concentration from approximately 100 to 100,
000 ng/mL in solution. This competitive assay avoided the
problem of "hook effect" as often encountered in non-competitive assays.
Through this study, the inventors demonstrate that gold
nanoparticles with their strong light scattering property, can
be used as a highly sensitive optical probe to replace traditional polymer latex particles for laser light scattering immunoassay development. The sensitivity and dynamic range of
such assays can be adjusted very conveniently to the expected
range by selecting appropriate nanoparticle probe concentrations and assay conditions. A single type of probe, or more
than one type of probes may be used for the assay. Both
competitive and non-competitive assay formats may be considered in the actual assay development for each individual
protein analyte.

Raman spectroscopy (Taton, T. A.; Mirkin, C. A.; Letsinger,
R. L. Science 2000, 289, 1757. (b) Cao, Y. W.; Jin, R. C.;
Mirkin, C. A. Science 2002, 297, 1536), have been developed
to improve the detection limit to femtomolar and attomolar
range. However, all these amplification methods involve
complicated multiple-step procedures that are not only time
consuming, but also often cause problems in reproducibility.
In this work, the inventors applied the invention for DNA
detection. As illustrated in FIG. 16, two sets of single stranded
DNA probes are functionalized onto citrate-protected gold
nanoparticles (DNAl-AuNP and DNA2-AuNP). When the
two DNA-functionalizedAuNP probes are mixed in a sample
solution that contains complementary target DNAs, the
hybridization of target DNA with two nanoparticle probes
will cause nanoparticles to form dimers, trimers, and larger
aggregates. This nanoparticle aggregation will increase the
average diameter of the whole nanoparticle population,
which can be detected by DLS analysis. The average diameter
increase of the nanoparticles can then be correlated quantitatively to the target DNA concentration. A higher target DNA
concentration should lead to more extensive nanoparticle
aggregation, and larger average nanoparticle size increase as
shown in FIG. 16.
In this work, the inventors synthesized a citrate-stabilized
gold nanoparticle with a core diameter of30 nm according to
a reported procedure (Turkevich, J.; Stevenson, P. C.; Hillier,
J. Discuss. Faraday Soc. 1951, 11, 55). Two DNA probes as
previously used in the work by Mirkin et al., are conjugated to
the gold nanoparticles (Jin, R.; Wu, G.; Li, Z.; Mirkin, C. A.;
and Schatz, G. C.J.Am. Chem. Soc. 2003, 125, 1643. Stoeva,
S. I.; Lee, J. S.; Thaxton, C. S.; and Mirkin, C. A. Angew.
Chem. Int. Ed. 2006, 45, 3303). FIG. 17a is the UV-Vis
absorption spectra of AuNPs probes before and after conjugating with DNA probes. The AuNP solution was initially
pinkish-red with a SPR band at 520 nm. Upon functionalization of single stranded DNA, the SPR band remained at 520
nm, indicating no particle aggregation due to an increased
repulsive interaction between nanoparticles after conjugating
with single stranded DNAs. DLS measurement was used to
monitor the size change of AuNPs before and after conjugating with the two DNA probes. As shown in FIG. 17b, the
hydrodynamic diameter of the nanoparticles increased
slightly from 29.0 nm to 34.4 nm for DNAl-AuNP and 38.2
nm for DNA2-AuNP, respectively. This hydrodynamic diameter change is caused by the addition of a DNA layer on the
nanoparticle surface. The DLS data also revealed a very narrow size distribution of AuNPs before and after DNA modification. Both UV-Vis absorption and DLS measurement
indicate that the DNA-AuNP probes remained to be individually dispersed in the solution.
For target DNA detection, a 1: 1 mixture solution of the two
DNA-AuNP probes at a concentration of 100 µM was added
to a set of target DNA solutions with a concentration ranging
from 5 µM to 5 nM. The concentration ofDNA-AuNP probes
was determined using UV-Vis absorption spectroscopy. The
mixed solution was incubated for 5 min at 70° C., and then
allowed to cool down to room temperature and set for 2 hours.
The solution was then diluted 100 fold for DLS measurement
(the DLS sample cell requires a 1-1.5 mL sample solution).
As shown in FIG. l8a, the average size of gold nanoparticles
in the control sample with 0 M target DNA in solution is
around 35.2 nm. In a sample solution containing 5 µM target
DNAs, the average nanoparticle size increased to 40.6 nm.
The whole nanoparticle population now contains the individually dispersed DNA-AuNP probes, nanoparticle dimers,
trimers and oligomers formed due to hybridization between
DNA targets and DNA probes. With increased concentration
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A one-step highly sensitive method for DNA detection
using dynamic light scattering. The inventors also demonstrated that this invention can be used for DNA detection and
analysis (Huo Q., et al. J. Am. Chem. Soc. 2008, 130, 81388139). There is a considerable demand for rapid, low-cost,
and sensitive detection of specific DNA sequences for the
clinical diagnosis of genetic and pathogenic diseases. Currently fluorescent optical label-based DNA detection methods such as DNA microarray and molecular beacons are
dominating the market. However, there are several limitations
in these widely adopted methods. One problem is the relatively low signal amplification. Because one DNA probe is
labeled with one or a few fluorophores, the fluorescence signal is rather weak when the target DNA concentration is low,
leading to relatively poor sensitivity. A second problem is the
poor photostability of typical fluorophores. Most organic
dyes suffer from serious photo bleaching and this often leads
to irreproducible results.
To solve some of these problems, several types of nanomaterials such as quantum dots, carbon nanotubes, silicon
nanowires, and metallic nanoparticles have been explored as
signaling probes for DNA detection. Among them, goldnanoparticles (AuNPs or GNPs) have been used in a variety of
forms for detecting DNAs based on their unique size and
distance-dependent optical properties. Mirkin and co-workers first developed a colorimetric detection of DNA hybridization in a homogeneous solution based on the formation of
oligonucleotide-functionalized AuNPs aggregates in the
presence of target DNAs (Elghanian, R.; Storhoff, J. J.;
Mucic, R. C.; Letsinger, R. L.; Mirkin, C. A. Science 1997,
277, 1078.) The nanoparticles aggregation can be detected
directly by observing the color change of the solution from
red to purple, or monitored by UV-Vis absorption spectroscopy. However, the main limitation of this approach is its low
sensitivity (10 nM). To increase the sensitivity, DNA bar code
amplification and other optical signal amplification techniques such as scanometric method, and surface enhanced
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of target DNAs, the average nanoparticle hydrodynamic
diameter increased accordingly. FIG. 19 is a plot of the particle size over the target DNA concentration from 5 µM to 5
nM. The detection limit is estimated to be around 1 µM.
Without any optimization, this detection limit is already 4
orders of magnitude higherthan absorption-basedmethods as
reported previously (Elghanian, R.; Storhoff, J. J.; Mucic, R.
C.; Letsinger, R. L.; Mirkin, C.A. Science 1997, 277, 1078).
The assay exhibits excellent reproducibility, as judged from
the small standard deviation of each concentration (three
samples were run for each concentration) and a good linearity
of the assay (see inset in FIG. 19).
To examine the selectivity of the new assay, the inventors
conducted a comparison study on single base pair-mismatched DNAs from perfectly matched DNA targets. Two
types of mismatched DNA targets were studied: one with a
mismatched pair located at the end and one with a mismatched pair in the middle of the target DNA sequence (mismatched sequences are shown in the Supporting Information
ofthepaperbytheinventors, Huo Q., eta!. J.Am. Chem. Soc.
2008, 130, 8138-8139). Under the exact same assay conditions, DLS analysis revealed a much less degree of nanoparticle aggregation when the target DNA has a single mismatched base pair, judging from the hydrodynamic diameter
of the nanoparticles as shown in FIG. l8b. This single base
pair mismatch study was conducted at a target DNA concentration of 10 µM. The result demonstrates the capability of our
new assay to discriminate single base pair-mismatched DNAs
from perfectly matched target DNAs, without using the melting transition ofDNA-nanoparticle aggregates as required by
a previously reported method (Elghanian, R.; Storhoff, J. J.;
Mucic, R. C.; Letsinger, R. L.; Mirkin, C. A. Science 1997,
277, 1078).
In conclusion, the inventors demonstrated a one-step
homogeneous hybridization assay for DNA detection based
on the invention. This assay is extremely easy to conduct,
provides much higher sensitivity compared to absorptionbased methods, however, without any signal amplification
process. Single base pair-mismatched DNAs can be readily
discriminated from perfectly complementary DNAs directly
from the DLS analysis under ambient conditions.

angle should be selected to detect nanoparticle aggregates
most sensitively. One example is a forward angle at 13 degree.
Other angles may be used as well depending on the type of
metal particles used and the assay formats. More than one
detector may be used for simultaneous analysis of multiple
samples. Outputs from detectors 211 and 212 are shown
coupled to a correlator or other type of processor 221 associated with a computer 230 which using correlation software
and is operable for determining the particle diffusion coefficients, and/or particle size and/or size distribution from the
correlation function. The data collection, processing, analysis
and display will be controlled by the computer 230. The
computer software will convert the DLS data to analyte concentration information. A linear or non-linear relation exists
between the DLS data of the assay solution and the analyte
concentration. The absolute analyte concentration may be
determined by comparison with a calibration curve obtained
using standard analyte solutions with known concentrations.
When standard analyte solutions are not available or it is not
necessary to obtain the absolute concentration of the analyte,
the nanoparticle diffusion coefficients, size and/ or size distribution data may be used directly to obtain the relative analyte
levels from different samples.
In other more specific embodiments, the invention pertains
to DLS systems that are particularly adapted to conduct assay
embodiments of multiple samples simultaneously or sequentially through automatic control. An example of such an
adapted DLS system with two different setups is illustrated in
FIG. 3. The first setup is used to analyze one sample solution
at a time (FIG. 3c) and the second setup is used to measure
multiple samples (means more than one sample) simultaneously (FIG. 3a and b). Other than the required components
for a basic DLS as shown in FIG. 2, this modified system 300
contains the following additional features/components: (1) a
laser beam 312 that can be split into multiple beams (or
multiple lasers) as incident light beams 322 for multiple assay
solutions 316, to thereby produce a scattered light signal 322;
(2) a movable platform 318 such as carousel that can hold one
or more than one assay solution containers. FIG. 3 illustrates
an example of a carousel 318 that has 12 assay solution
containers 316 or cell holders where cells that contain the
assay solutions can be loaded to the holder manually or automatically. The carousel 318 may be a stand-alone device. The
carousel 318 will be inserted into the D LS main system manually or automatically. The carousel may also rotate in-plane as
illustrated in FIG. 3b (326). The system 300 may optionally
include a liquid handling system 324 for delivering and/or
removing fluid from the cells.
Generally, the DLS is equipped with a single or multiple
detectors. The number of detectors may match the number of
sample solution containers in the carousel. The number of
detectors may be smaller than the number of sample solution
containers in the carousel. Each detector will detect the scattered light signal from one sample solution. The data collected from each detector may be processed by the same
processor such as correlator sequentially or multiple processors simultaneously to obtain the correlation function of each
assay solution. As an example, FIG. 3 illustrates that 12
samples may be analyzed simultaneously using one laser
source and 12 detectors. Alternatively, one can turn on only
one detector, load one sample to the carousel a time. By
rotating the carousel, the user can continuously load a new
sample and unload the analyzed sample from the carousel so
that multiple samples may be analyzed sequentially. FIG. 3 is
only an illustration. Other settings that are based on the
sample concept may be adapted as well. For example, the
carousel may contain any number of sample solution contain-
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Example 7
DLS Systems
FIG. 2 shows a basic DLS system 200 according to the
invention for determining the presence of analytes in one
sample at a time manually. System 200 comprises a vessel/
cell 204 formed from an optically transparent material for
holding a sample solution suspected of containing at least one
target analyte, and the same or two different nanoprobes
conjugated with receptors. The receptors can be the same or
different. A light source, such as laser 210 directs light with a
suitable wavelength (e.g. ultraviolet, visible, near infrared, or
infrared) at the analyte comprising solution which is contained in a vessel/cell 204. An attenuator 217 may or may not
be used to adjust the intensity of the incident laser beam from
laser 210. At least one detector, such as detectors 211 and 212,
is provided for measuring a scattered light signal from the
analyte comprising solution. The detector may be placed at
different angles in relative to the incident laser beam, from 0
to 180 degree angle, in a more specific embodiment, 0-90
degree. In one embodiment, the analyte detected excludes
DNA, or if DNA is the target analyte, the detector relative to
the laser must be between 0-90 degrees. At different detector
angles, the sensitivity of the assay may vary. A best detector
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ers or cell holders other than 12. The carousel may be replaced
by a microfluidic device with sample solution containers
embedded in the device. The carousel may also be replaced by
a device that does not have the circular shape as shown in FIG.
3, but functions the same as a carousel. The different modes as
discussed above (fixed carousel versus rotatable carousel
using single or multiple detectors simultaneously) may be
combined together to speed up the assay and reduce the cost.
Shown in FIG. 3c is an alternative embodiment that provides for a reduction in the amount ofDLS detectors needed
but also allows the user the ability to manipulate samples in
and out of the movable platform expediently. System 350
includes a movable platform 355 that has at least a first
container 354 and a second container 356. The movable platform 355 may shift one or the other containers 354, 356 from
a load zone 357 to a detection zone 359. The light source 351
sends an incidental light beam 358 at the container in the
detection zone 359 to thereby produce a scattered light signal
360. The detector 361 detects the scattered light signal for
further processing by a computer.
For both DLS systems, a computer software will be used to
control the liquid mixing, sample loading and unloading, and
the DLS measurement; to process the scattering light intensity data into correlation function; to process the correlation
function data into particle diffusion coefficient, particle size
and/or size distribution information; and to process such
information into analyte concentration (including relative or
absolute concentration) with and without the use of a calibration curve. Calibration curve is established by assaying a
series of standard sample solution with known concentration
of analytes. Typically, comparison ofDLS data obtained from
an unknown sample solution with the calibration curve will
reveal the analyte concentration in the unknown sample.
As will be appreciated by one of skill in the art, embodiments of the present invention may be embodied as a device
or system comprising a processing module, and/or computer
program product comprising at least one program code module. Accordingly, the present invention may take the form of
an entirely hardware embodiment or an embodiment combining software and hardware aspects. Furthermore, the present
invention may include a computer program product on a
computer-usable storage medium having computer-usable
program code means embodied in the medium. Any suitable
computer readable medium may be utilized including hard
disks, CD-ROMs, DVDs, optical storage devices, or magnetic storage devices.
The term "processing module" may include a single processing device or a plurality of processing devices. Such a
processing device may be a microprocessor, micro-controller, digital signal processor, microcomputer, central processing unit, field programmable gate array, programmable logic
device, state machine, logic circuitry, analog circuitry, digital
circuitry, and/or any device that manipulates signals (analog
and/or digital) based on operational instructions. The processing module may have operationally coupled thereto, or
integrated therewith, a memory device. The memory device
may be a single memory device or a plurality of memory
devices. Such a memory device may be a read-only memory,
random access memory, volatile memory, non-volatile
memory, static memory, dynamic memory, flash memory,
and/or any device that stores digital information. A computer,
as used herein, is a device that comprises at least one processing module, and optionally at least one memory device.
The computer-usable or computer-readable medium may
be or include, for example, but not limited to, an electronic,
magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, device, or propagation medium. More

specific examples (a non-exhaustive list) of the computerreadable medium would include the following: an electrical
connection having one or more wires, a portable computer
diskette, a random access memory (RAM), a read-only
memory (ROM), an erasable programmable read-only
memory (EPROM or Flash memory), an optical fiber, and a
portable compact disc read-only memory (CD-ROM), a CD
ROM, a DVD (digital video disk), or other electronic storage
medium. Note that the computer-usable or computer-readable medium could even be paper or another suitable medium
upon which the program is printed, as the program can be
electronically captured, via, for instance, optical scarming of
the paper or other medium, then compiled, interpreted or
otherwise processed in a suitable marmer if necessary, and
then stored in a computer memory.
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Computer program code for carrying out operations of
certain embodiments of the present invention may be written
in an object oriented and/or conventional procedural programming languages including, but not limited to, Java,
Smalltalk, Peri, Python, Ruby, Lisp, PHP, "C", FORTRAN,
or C++. The program code may execute entirely on the user's
computer, partly on the user's computer, as a stand-alone
software package, partly on the user's computer and partly on
a remote computer or entirely on the remote computer. In the
latter scenario, the remote computer may be connected to the
user's computer through a local area network (LAN) or a
wide area network (WAN), or the connection may be made to
an external computer (for example, through the Internet using
an Internet Service Provider).
It will be understood that functions of DLS systems
described herein may be implemented by computer-readable
program code modules. These program code modules may be
provided to a processing module of a general purpose computer, special purpose computer, embedded processor or
other programmable data processing apparatus to produce a
machine, such that the program code modules, which execute
via the processing module of the computer or other programmable data processing apparatus, create means for implementing the functions specified in the flowchart and/or block
diagram block or blocks.

These computer program code modules may also be stored
in a computer-readable memory that can direct a computer or
other progranimable data processing apparatus to function in
a particular manner, such that the program code modules
stored in the computer-readable memory produce an article of
manufacture.
The computer program code modules may also be loaded
onto a computer or other programmable data processing
apparatus to cause a series of operational steps to be performed on the computer or other progranimable apparatus to
produce a computer implemented process such that the
instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart and/or block diagram block or
blocks.
This invention can be embodied in other forms without
departing from the spirit or essential attributes thereof and,
accordingly, reference should be to the following claims
rather than the foregoing specification as indicating the scope
of the invention.
The disclosure of all references cited are incorporated in
their entirety to the extent not inconsistent with the teachings
herein.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 3
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 12
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
probe

<400> SEQUENCE, 1
12

taacaatccc tc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 15
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
probe

<400> SEQUENCE, 2
15

atccttatca atatt

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 30
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
gagggattat tgttaaatat tgataaggat

What is claimed is:
1. A dynamic light scattering (DLS) apparatus for assaying
multiple sample solutions simultaneously, said system comprising:
a computer;
a carousel housing comprising a plurality of containers for
holding a plurality of sample solutions
a light source interior to the carousel that delivers incidenta! light to a side of each container of said plurality of
containers simultaneously to produce scattered light that
exits out of the side of each container;
a display;
a plurality of detectors each arranged so as to sense light
scattering of said multiple samples, wherein said scattered light that exits out of the side of each container is
detected simultaneously, wherein the plurality of detec-
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tors are placed to detect the scattered light at a scattering
angle between zero and ninety degrees;
a first program code module for directing said computer to
initiate lighting said multiple samples;
a second program code module for measuring light scattering from said cell and processing light scattering signal into DLS data;
a third program code module for directing said computer to
process DLS data of individual samples into relative or
absolute analyte concentration information; and
a fourth program code module for directing said computer
to display said information on a display device, wherein
said DLS data is obtained from two or more samples of
said multiple samples simultaneously.

* * * * *

